Breaking News

Lonza Expands Single-Use Manufacturing Capacity

January 13, 2016

Adds two 1000L single-use bioreactor systems to its current mammalian manufacturing capacity

Lonza has expanded mammalian production capacity at its Slough, UK facility. Based on the increased demand for biopharmaceutical development and clinical manufacturing services, two 1000L single-use bioreactors will be installed at the site. According to the company, this expansion will significantly increase the existing single-use manufacturing capacity in Slough while allowing current operations to continue without interruption.

Lonza’s cGMP facility in Slough is its center of excellence for development and clinical supply. The site provides cell line construction, process development and clinical manufacturing services for mammalian-derived biotherapeutics.

The increase in bioreactor capacity continues the implementation of single-use technologies at the Slough site and complements existing single-use equipment for both seed train systems and downstream processing, including chromatography, filtration and ultrafiltration unit operations. The new reactors are equipped with controllers that enable parallel reactor operations, expanded process capabilities with flexible operating scales and bioreactor types. Use of these technologies supports Lonza’s ability to accommodate a variety of customer projects and processes across scales and clinical phases.

“The ease of installation, commissioning and validation of single-use bioreactors allows us to meet the increased market demand for clinical manufacturing,” said Michael Brown, head of operations for clinical development, Lonza Pharma&Biotech.

Related Contract Manufacturing:

Related Compliance:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks